These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30426647)

  • 21. Localized delivery of immunotherapeutics: A rising trend in the field.
    Wang J; Zhang Y; Pi J; Xing D; Wang C
    J Control Release; 2021 Dec; 340():149-167. PubMed ID: 34699871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody engineering, virus retargeting and cellular immunotherapy: one ring to rule them all?
    Sanz L; Qiao J; Vile RG; Alvarez-Vallina L
    Curr Gene Ther; 2005 Feb; 5(1):63-70. PubMed ID: 15638711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer immunotherapy from biology to nanomedicine.
    Abdelbaky SB; Ibrahim MT; Samy H; Mohamed M; Mohamed H; Mustafa M; Abdelaziz MM; Forrest ML; Khalil IA
    J Control Release; 2021 Aug; 336():410-432. PubMed ID: 34171445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Competitive Affinity Release for Long-Term Delivery of Antibodies from Hydrogels.
    Huynh V; Wylie RG
    Angew Chem Int Ed Engl; 2018 Mar; 57(13):3406-3410. PubMed ID: 29392857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Progress of study on antitumor effects of antibody dependent cell mediated cytotoxicity--review].
    Qu YH; Li Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1370-5. PubMed ID: 21129296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New solid tumor targets for therapeutic monoclonal antibodies.
    Papkoff J
    Expert Opin Ther Targets; 2007 May; 11(5):585-8. PubMed ID: 17465718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibodies for treating and preventing disease: the potential role of polymeric controlled release.
    Saltzman WM
    Crit Rev Ther Drug Carrier Syst; 1993; 10(2):111-42. PubMed ID: 8370084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An overview of cancer immunotherapeutic strategies.
    Wahid B; Ali A; Rafique S; Waqar M; Wasim M; Wahid K; Idrees M
    Immunotherapy; 2018 Aug; 10(11):999-1010. PubMed ID: 30149763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.
    Wu J; Fu J; Zhang M; Liu D
    J Hematol Oncol; 2015 Aug; 8():96. PubMed ID: 26231785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Engineering Protein Delivery Depots for Cancer Immunotherapy.
    Wen D; Chen G; Chen Q; Li PY; Cheng H; Gu Z
    Bioconjug Chem; 2019 Mar; 30(3):515-524. PubMed ID: 30839198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunotherapy and cancer: the role of monoclonal antibodies].
    Dumontet C
    J Chir (Paris); 1989 Dec; 126(12):682-6. PubMed ID: 2695534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy as an Option for Cancer Treatment.
    Rusch T; Bayry J; Werner J; Shevchenko I; Bazhin AV
    Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):89-96. PubMed ID: 29026920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.
    Young PA; Morrison SL; Timmerman JM
    Semin Oncol; 2014 Oct; 41(5):623-36. PubMed ID: 25440607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chitosan-based hydrogels for controlled, localized drug delivery.
    Bhattarai N; Gunn J; Zhang M
    Adv Drug Deliv Rev; 2010 Jan; 62(1):83-99. PubMed ID: 19799949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controlled release of an anthrax toxin-neutralizing antibody from hydrolytically degradable polyethylene glycol hydrogels.
    Liang Y; Coffin MV; Manceva SD; Chichester JA; Jones RM; Kiick KL
    J Biomed Mater Res A; 2016 Jan; 104(1):113-23. PubMed ID: 26223817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved Mechanical Properties and Sustained Release Behavior of Cationic Cellulose Nanocrystals Reinforeced Cationic Cellulose Injectable Hydrogels.
    You J; Cao J; Zhao Y; Zhang L; Zhou J; Chen Y
    Biomacromolecules; 2016 Sep; 17(9):2839-48. PubMed ID: 27519472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody engineering: facing new challenges in cancer therapy.
    Sanz L; Cuesta AM; Compte M; Alvarez-Vallina L
    Acta Pharmacol Sin; 2005 Jun; 26(6):641-8. PubMed ID: 15916728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineering nanoparticle strategies for effective cancer immunotherapy.
    Yoon HY; Selvan ST; Yang Y; Kim MJ; Yi DK; Kwon IC; Kim K
    Biomaterials; 2018 Sep; 178():597-607. PubMed ID: 29576282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics.
    Van Herck S; De Geest BG
    Acta Pharmacol Sin; 2020 Jul; 41(7):881-894. PubMed ID: 32451411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineered in-situ depot-forming hydrogels for intratumoral drug delivery.
    Fakhari A; Anand Subramony J
    J Control Release; 2015 Dec; 220(Pt A):465-475. PubMed ID: 26585504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.